These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9785 related articles for article (PubMed ID: 20689768)

  • 1. Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET.
    Honer M; Ebenhan T; Allegrini PR; Ametamey SM; Becquet M; Cannet C; Lane HA; O'Reilly TM; Schubiger PA; Sticker-Jantscheff M; Stumm M; McSheehy PM
    Transl Oncol; 2010 Aug; 3(4):264-75. PubMed ID: 20689768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
    J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies.
    Jensen MM; Kjaer A
    Am J Nucl Med Mol Imaging; 2015; 5(5):431-56. PubMed ID: 26550536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
    Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
    Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.
    Li Z; Graf N; Herrmann K; Jünger A; Aichler M; Feuchtinger A; Baumgart A; Walch A; Peschel C; Schwaiger M; Buck A; Keller U; Dechow T
    Cancer Res; 2012 Oct; 72(19):5014-24. PubMed ID: 22875026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.
    Cullinane C; Waldeck KL; Binns D; Bogatyreva E; Bradley DP; de Jong R; McArthur GA; Hicks RJ
    Nucl Med Biol; 2014 Feb; 41(2):148-54. PubMed ID: 24332383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model.
    Brepoels L; Stroobants S; Verhoef G; De Groot T; Mortelmans L; De Wolf-Peeters C
    J Nucl Med; 2009 Jul; 50(7):1102-9. PubMed ID: 19525456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
    Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
    J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
    Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
    Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
    Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
    Moroz MA; Kochetkov T; Cai S; Wu J; Shamis M; Nair J; de Stanchina E; Serganova I; Schwartz GK; Banerjee D; Bertino JR; Blasberg RG
    Clin Cancer Res; 2011 Mar; 17(5):1099-110. PubMed ID: 21245090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging.
    Wang FL; Tan YY; Gu XM; Li TR; Lu GM; Liu G; Huo TL
    Chin Med J (Engl); 2016 Dec; 129(24):2926-2935. PubMed ID: 27958224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.
    Wang H; Zhang J; Tian J; Qu B; Li T; Chen Y; Liu J; Wang S
    J Nucl Med; 2009 Nov; 50(11):1857-64. PubMed ID: 19837754
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Xu W; Yu S; Xin J; Guo Q
    Exp Ther Med; 2016 Dec; 12(6):4154-4158. PubMed ID: 28101193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
    Geven EJ; Evers S; Nayak TK; Bergström M; Su F; Gerrits D; Franssen GM; Boerman OC
    Contrast Media Mol Imaging; 2015; 10(3):203-10. PubMed ID: 25204436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase of [(18)F]FLT tumor uptake in vivo mediated by FdUrd: toward improving cell proliferation positron emission tomography.
    Viertl D; Bischof Delaloye A; Lanz B; Poitry-Yamate C; Gruetter R; Mlynarik V; Ametamey SM; Ross TL; Lehr HA; André PA; Perillo-Adamer F; Kosinski M; Dupertuis YM; Buchegger F
    Mol Imaging Biol; 2011 Apr; 13(2):321-31. PubMed ID: 20556524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma.
    Wei LH; Su H; Hildebrandt IJ; Phelps ME; Czernin J; Weber WA
    Clin Cancer Res; 2008 Jun; 14(11):3416-26. PubMed ID: 18519772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
    Ullrich RT; Zander T; Neumaier B; Koker M; Shimamura T; Waerzeggers Y; Borgman CL; Tawadros S; Li H; Sos ML; Backes H; Shapiro GI; Wolf J; Jacobs AH; Thomas RK; Winkeler A
    PLoS One; 2008; 3(12):e3908. PubMed ID: 19079597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of [18F]-tracers in various experimental tumor models by PET imaging and identification of an early response biomarker for the novel microtubule stabilizer patupilone.
    Ebenhan T; Honer M; Ametamey SM; Schubiger PA; Becquet M; Ferretti S; Cannet C; Rausch M; McSheehy PM
    Mol Imaging Biol; 2009; 11(5):308-21. PubMed ID: 19462209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 490.